Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Unfractionated heparin is most common in the anticoagulation management of V-V ECMO. However,
many side effects of unfractionated heparin, such as HIT, antithrombin deficiency, etc
seriously affects the prognosis of patients. Argatroban is kind of direct thrombin
inhibitors, which could be used used as an alternative anticoagulant of unfractionated
heparin when HIT or antithrombin deficiency, etc. At present, there is no power enough
evidence for the application of argatroban in V-V ECMO. This study aims to evaluat the safety
and effectiveness of argatroban in the anticoagulation management of V-V ECMO compared with
unfractionated heparin.